Levels of phosphodiesterase 4A and 4B are altered by chronic treatment with psychotropic medications in rat frontal cortex

S H Fatemi, Timothy D. Folsom, Teri J. Reutiman, Natalie N. Braun, Luke G. Lavergne

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Our laboratory has recently demonstrated altered expression of phosphodiesterase (PDE) 4A and 4B in subjects with autism, bipolar disorder, and schizophrenia, suggesting disrupted cAMP signaling in these diagnostic groups. In the current study, we measured expression of PDEs in rat frontal cortex (FC) following chronic treatment with clozapine, fluoxetine, haloperidol, lithium, olanzapine, valproic acid (VPA), or sterile saline for 21 days. Western blotting experiments showed decreased expression of PDE4A subtypes in FC following treatment with clozapine, haloperidol, lithium, and VPA. PDE4B subtypes were similarly reduced in FC following treatment with clozapine, fluoxetine, and lithium. We also measured levels of nine PDE subtypes via qRT-PCR in FC and found significant upregulation of PDE1A and PDE8B following treatment with olanzapine, while treatment with lithium reduced expression of mRNA for PDE8B. Our results demonstrate altered expression of PDE4A and PDE4B in response to a variety of psychotropic medications suggesting potentially new therapeutic avenues for treatment of neuropsychiatric diseases.

Original languageEnglish (US)
Pages (from-to)550-555
Number of pages6
JournalSynapse
Volume64
Issue number7
DOIs
StatePublished - Jul 1 2010

Keywords

  • Frontal cortex
  • Phosphodiesterase 4A
  • Phosphodiesterase 4B
  • Rat
  • Schizophrenia

Fingerprint Dive into the research topics of 'Levels of phosphodiesterase 4A and 4B are altered by chronic treatment with psychotropic medications in rat frontal cortex'. Together they form a unique fingerprint.

Cite this